bpc 157 immunogenicity BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 – Research Peptide |

Not FDA approved

However, due to poor metabolic stability of angiotensin IV and many AnglV analogues, the inability of early analogues to penetrate the blood brain baixier, and the failure to identify the AT4 receptor, no pharmaceutical company has moved forward with their development

Hes applying to the Advanced Research Projects Agency for Health, or ARPA-H, a government agency specifically dedicated to funding high-risk, high-reward research that could transform health care or fail entirely

As the systematic review noted: No clinical safety data were found. When the FDA says insufficient evidence, they mean itwe literally do not have the data to know whether chronic BPC-157 use causes problems that emerge years down the road